Tumor Necrosis Factor Alpha Inhibitors in Pediatric Rheumatology

Selahaddin CEVİZBAŞa , Tuncay AYDINa , Şevket Erbil ÜNSALa

aDokuz Eylül University Faculty of Medicine, Department of Pediatric Rheumatology, İzmir, Türkiye

ABSTRACT
The identification of cytokine tumor necrosis factor alpha (TNF-α), known for its crucial role in inflammation, along with the development of new biotechnological methods to obstruct it, has resulted in introducing biological drugs in rheumatology. Biologics drugs are technologically advanced and expensive drugs that specifically target immunological or genetic mediators involved in the disease’s pathogenesis. TNF-inhibitors represent one of the primary biological drug classes used in pediatric rheumatology. These were the primary biologic disease-modifying drugs to be developed and have been used for treating autoimmune diseases for over two decades. Therapeutic approaches focused on inhibiting TNF-α have proven to be highly beneficial in the treatment of chronic autoimmune diseases like juvenile idiopathic arthritis, ankylosing spondylitis, and psoriatic arthritis. Introducing these agents has made remission a more achievable aim in the treatment of various rheumatological conditions. The current article will examine the use of TNF-α inhibitors in pediatric rheumatology.
Keywords: Tumor necrosis factor inhibitors; rheumatology

Referanslar

  1. Marino A, Giani T, Cimaz R. Risks associated with use of TNF inhibitors in children with rheumatic diseases. Expert Rev Clin Immunol. 2019;15(2):189-98. [Crossref]  [PubMed]
  2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344(12):907-16. [Crossref]  [PubMed]
  3. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72(9):3666-70. [Crossref]  [PubMed]  [PMC]
  4. Kelker HC, Oppenheim JD, Stone-Wolff D, Henriksen-DeStefano D, Aggarwal BB, Stevenson HC, et al. Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin. Int J Cancer. 1985;36(1):69-73. [Crossref]  [PubMed]
  5. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651-65. [Crossref]  [PubMed]  [PMC]
  6. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11(9):372-7. [Crossref]  [PubMed]
  7. Er Gülbezer E, Keser G. Biological treatments. RAED Derg. 2017;9(1-2):11-31. [Crossref]
  8. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-79. [Crossref]  [PubMed]
  9. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49(7):1215-28. [Crossref]  [PubMed]  [PMC]
  10. Mootoo A, Stylianou E, Arias MA, Reljic R. TNF-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets. 2009;8(1):53-62. [Crossref]  [PubMed]
  11. Vinay DS, Kwon BS. The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol. 2011;164 (2):145-57. [Crossref]  [PubMed]  [PMC]
  12. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785-96.e3. [Crossref]  [PubMed]
  13. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res. 2015;165(2):270-82. [Crossref]  [PubMed]
  14. Aydın V, Akıcı A. TNF-alpha inhibitor-induced infections in rheumatic diseases. J Turkish Fam Physician. 2018;9(1):13-24. [Crossref]
  15. Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56-63. [Crossref]  [PubMed]
  16. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337(3):141-7. [Crossref]  [PubMed]
  17. Cimaz R, Maioli G, Calabrese G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2020;20(7):725-740. [Crossref]  [PubMed]
  18. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342 (11):763-9. [Crossref]  [PubMed]
  19. Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kümmerle-Deschner J, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford). 2009;48(8):916-9. [Crossref]  [PubMed]
  20. Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol. 2015;67 (8):2240-9. [Crossref]  [PubMed]
  21. Hugle B, Burgos-Vargas R, Inman RD, O'Shea F, Laxer RM, Stimec J, et al. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol. 2014;32(3):424-31.
  22. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519-25. [Crossref]  [PubMed]
  23. Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Paediatric Rheumatology International Trials Organisation (PRINTO). Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6): 1114-22. [Crossref]  [PubMed]  [PMC]
  24. Katsicas MM, Russo R. Biologic agents in juvenile spondyloarthropathies. Pediatr Rheumatol. 2016;14(1):1-8. [Crossref]  [PubMed]  [PMC]
  25. Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256. [Crossref]  [PubMed]  [PMC]
  26. Unsal E. Using Biologic Agents in Pediatric Rheumatologic Diseases. Antiinflamm Antiallergy Agents Med Chem. 2012;9(1):41-45. [Crossref]
  27. Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, et al. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016;18(1):210. [Crossref]  [PubMed]  [PMC]
  28. Becker I, Horneff G. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2017;69(4):552-60. [Crossref]  [PubMed]
  29. Nimmrich S, Horneff G. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Rheumatol Int. 2015;35(3):465-70. [Crossref]  [PubMed]
  30. Wang F, Wang NS. Etanercept therapy-associated acute uveitis: A case report and literature review. Clin Exp Rheumatol. 2009;27(5):838-9.
  31. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-α treatment: A possible promoter in endogenous uveitis observational report on six patients: Occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35(8):751-6. [Crossref]  [PubMed]
  32. Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75 (5):855-61. [Crossref]  [PubMed]
  33. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K; German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(6):1015-9. [Crossref]  [PubMed]
  34. Pastore S, Naviglio S, Canuto A, Lepore L, Martelossi S, Ventura A, Taddio A. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting. Paediatr Drugs. 2018;20(2):165-71. [Crossref]  [PubMed]
  35. Okihiro A, Hasija R, Fung L, Cameron B, Feldman BM, Laxer R, et al. Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatr Rheumatol Online J. 2018;16(1):17. [Crossref]  [PubMed]  [PMC]
  36. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496-504. [Crossref]  [PubMed]
  37. van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003;62 (12):1168-77. [Crossref]  [PubMed]  [PMC]
  38. Chen X, Bäumel M, Männel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007;179(1):154-61. [Crossref]  [PubMed]
  39. Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J Exp Med. 2016;213(7):1241-53. [Crossref]  [PubMed]  [PMC]
  40. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810-20. [Crossref]  [PubMed]
  41. Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433-41. [Crossref]  [PubMed]  [PMC]
  42. Brunner HI, Nanda K, Toth M, Foeldvari I, Bohnsack J, Milojevic D, et al. Paediatric Rheumatology International Trials Organisation, and the Pediatric Rheumatology Collaborative Study Group. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care Res (Hoboken). 2020;72(10):1420-30. [Crossref]  [PubMed]  [PMC]
  43. Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, et al. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis Care Res (Hoboken). 2015;67(11):1503-12. [Crossref]  [PubMed]  [PMC]
  44. D'Angelo S, Cantini F, Ramonda R, Cantarini L, Carletto A, Chimenti MS, et al. Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. Front Pharmacol. 2019;10:1497. [Crossref]  [PubMed]  [PMC]
  45. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572-5. [Crossref]  [PubMed]
  46. Tynjälä P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339-44. [Crossref]  [PubMed]
  47. LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181-8. [Crossref]  [PubMed]
  48. Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. SYCAMORE Study Group. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17): 1637-46. [Crossref]  [PubMed]
  49. Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. French Uveitis Network. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis Rheumatol. 2016;68(6):1522-30. [Crossref]  [PubMed]
  50. Robinson AB, Gallentine WB, Rabinovich CE. Pediatric neuro-Behçet's disease responsive to adalimumab. Pediatr Neurol. 2010;43(4):291-3. [Crossref]  [PubMed]
  51. Marsili M, Marzetti V, Lucantoni M, Lapergola G, Gattorno M, Chiarelli F, et al. Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report. Ital J Pediatr. 2016;42(1):81. [Crossref]  [PubMed]  [PMC]
  52. Poddighe D, Mukusheva Z, Dauyey K, Assylbekova M. Adalimumab in the treatment of pediatric Behçet's disease: case-based review. Rheumatol Int. 2019;39(6):1107-12. [Crossref]  [PubMed]
  53. Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015;14(7):1111-26. [Crossref]  [PubMed]
  54. Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs. 2009;69(11):1403-15. [Crossref]  [PubMed]
  55. Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, et al. EULAR. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704-12. [Crossref]  [PubMed]
  56. Taylor PC. Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford). 2005;44(6):721-8. [Crossref]  [PubMed]
  57. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096-106. [Crossref]  [PubMed]
  58. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005;52(7):2103-8. [Crossref]  [PubMed]
  59. Taddio A, Cattalini M, Simonini G, Cimaz R. Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2016;12(6):641-9. [Crossref]  [PubMed]
  60. Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718-22. [Crossref]  [PubMed]  [PMC]
  61. Kosmač M, Avčin T, Toplak N, Simonini G, Cimaz R, Curin Šerbec V. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res. 2011;69(3):243-8. [Crossref]  [PubMed]
  62. Aeschlimann FA, Angst F, Hofer KD, Cannizzaro Schneider E, Schroeder-Kohler S, Lauener R, et al. Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study. J Rheumatol. 2017;44(3):334-41. [Crossref]  [PubMed]
  63. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552-63. [Crossref]  [PubMed]
  64. Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014;66(7):1073-84. [Crossref]  [PubMed]
  65. Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144(6):844-9. [Crossref]  [PubMed]  [PMC]
  66. Simonini G, Zannin ME, Caputo R, Falcini F, de Martino M, Zulian F, Cimaz R. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008;47(10):1510-4. [Crossref]  [PubMed]
  67. Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, et al.. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74-9. [Crossref]  [PubMed]
  68. Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta S, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis. 2013;19(6):1224-31. [Crossref]  [PubMed]
  69. Deeks ED. Certolizumab pegol: A review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(1):75-97. [Crossref]  [PubMed]
  70. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286-92; quiz e24. [Crossref]  [PubMed]  [PMC]
  71. Shim H. One target, different effects: A comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med. 2011;43(10):539-549. [Crossref]  [PubMed]  [PMC]
  72. Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21-9. [Crossref]  [PubMed]  [PMC]